News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InSite Vision (ISV) Fully Enrolls Phase 3 DOUBle Clinical Study of AzaSite Plus™ and DexaSite™ for Blepharitis


9/7/2012 10:13:22 AM

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV) today announced that patient enrollment has been completed in the DOUBle Phase 3 clinical trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) for the treatment of blepharitis. The DOUBle (Dual Ophthalmic agents Used in Blepharitis) study enrolled more than 900 patients with moderate-to-severe blepharitis in less than ten months in a four-arm trial designed to evaluate the efficacy and safety of both product candidates simultaneously.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES